Muhammet Ali Kaplan1, Sukru Ozaydin2, Halis Yerlikaya3, Mustafa Karaagac4, Mahmut Gumus5, Timucin Cil6, Ülkü Yalcintas Arslan7, Nuriye Ozdemir8, Abdullah Sakin9, Mehmet Bilici10, Dogan Koca11, Mukremin Uysal12, Faysal Dane13, Özlem Nuray Sever14, Mehmet Metin Seker15, Zeynep Oruc Seker3, Mehmet Fatih Can2, Caglayan Geredeli4, Asude Aksoy16, Keziban Nur Pilanci17, Turkan Ozturk Topcu18, Abdurrahman Isikdogan3. 1. Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey, drmalikaplan@hotmail.com. 2. Department of Medical Oncology, Gulhane Education and Research Hospital, Ankara, Turkey. 3. Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey. 4. Department of Medical Oncology, Konya Numune Training and Research Hospital, Konya, Turkey. 5. Department of Medical Oncology, Faculty of Medicine, Medeniyet University, Istanbul, Turkey. 6. Department of Medical Oncology, Adana Numune Education and Research Hospital, Adana, Turkey. 7. Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey. 8. Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey. 9. Department of Medical Oncology, Okmeydani Education and Research Hospital, Ankara, Turkey. 10. Department of Medical Oncology, Atatürk University, Erzurum, Turkey. 11. Department of Medical Oncology, Kocaeli Medikal Park Hospital, Kocaeli, Turkey. 12. Department of Medical Oncology, Afyon Kocatepe University, Afyonkarahisar, Turkey. 13. Department of Medical Oncology, Medical Oncology, Marmara University, Istanbul, Turkey. 14. Department of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey. 15. Medical Oncology Department, Cumhuriyet University Faculty of Medicine, Sivas, Turkey. 16. Department of Medical Oncology, Faculty of Medicine, Fırat University, Malatya, Turkey. 17. Department of Medical Oncology, Bilim University, Istanbul, Turkey. 18. Department of Medical Oncology, Karadeniz Technical University School of Medicine, Trabzon, Turkey.
Abstract
BACKGROUND: Colorectal cancer (CRC) is a rare disease amongst children and adolescents. Previous studies have reported a number of differences between children/adolescents, young adults, and adult patients with CRC. However, none of these studies compared these age groups according to their clinicopathologic and prognostic characteristics. In the current study, we compare these three age groups. METHODS: A total of 173 (1.1% of 15,654 patients) young CRC patients (≤25 years) were included in the study. As a control group, 237 adult CRC patients (>25 years) were also included. Patients were divided into three age groups: child/adolescent (10-19 years), young adult (20-25 years), and adult (>25 years). RESULTS: Statistical differences amongst the three groups in terms of gender (p = 0.446), family history (p = 0.578), symptoms of presentation (p = 0.306), and interval between initiation of symptoms and diagnosis (p = 0.710) could not be demonstrated. Whilst abdominal pain (p < 0.001) and vomiting (p = 0.002) were less common in young adults than in other groups, rectal bleeding and changes in bowel habits were relatively less common in adolescents than in other groups. Rectal localisation (p = 0.035), mucinous adenocarcinoma (p < 0.001), and a poorly differentiated histologic subtype (p < 0.001) were less common in the adult group than in other groups. The percentage of patients with metastasis and sites of metastasis (e.g., peritoneum and lung) differed between groups. The median overall survival was 32.6 months in the adolescent group, 57.8 months in the young adult group and was not reached in the adult group (p = 0.022). The median event-free survival of the adolescent, young adult, and adult groups was 29.0, 29.9, and 61.6 months, respectively (p = 0.003). CONCLUSIONS: CRC patients of different age groups present different clinicopathologic and prognostic characteristics. Clinicians should be aware of and manage the disease according to these differences.
BACKGROUND:Colorectal cancer (CRC) is a rare disease amongst children and adolescents. Previous studies have reported a number of differences between children/adolescents, young adults, and adult patients with CRC. However, none of these studies compared these age groups according to their clinicopathologic and prognostic characteristics. In the current study, we compare these three age groups. METHODS: A total of 173 (1.1% of 15,654 patients) young CRCpatients (≤25 years) were included in the study. As a control group, 237 adult CRCpatients (>25 years) were also included. Patients were divided into three age groups: child/adolescent (10-19 years), young adult (20-25 years), and adult (>25 years). RESULTS: Statistical differences amongst the three groups in terms of gender (p = 0.446), family history (p = 0.578), symptoms of presentation (p = 0.306), and interval between initiation of symptoms and diagnosis (p = 0.710) could not be demonstrated. Whilst abdominal pain (p < 0.001) and vomiting (p = 0.002) were less common in young adults than in other groups, rectal bleeding and changes in bowel habits were relatively less common in adolescents than in other groups. Rectal localisation (p = 0.035), mucinous adenocarcinoma (p < 0.001), and a poorly differentiated histologic subtype (p < 0.001) were less common in the adult group than in other groups. The percentage of patients with metastasis and sites of metastasis (e.g., peritoneum and lung) differed between groups. The median overall survival was 32.6 months in the adolescent group, 57.8 months in the young adult group and was not reached in the adult group (p = 0.022). The median event-free survival of the adolescent, young adult, and adult groups was 29.0, 29.9, and 61.6 months, respectively (p = 0.003). CONCLUSIONS:CRCpatients of different age groups present different clinicopathologic and prognostic characteristics. Clinicians should be aware of and manage the disease according to these differences.
Authors: Fanny E R Vuik; Stella A V Nieuwenburg; Iris D Nagtegaal; Ernst J Kuipers; Manon C W Spaander Journal: Aliment Pharmacol Ther Date: 2021-10-12 Impact factor: 9.524
Authors: Matthew Castelo; Colin Sue-Chue-Lam; Lawrence Paszat; Teruko Kishibe; Adena S Scheer; Bettina E Hansen; Nancy N Baxter Journal: PLoS One Date: 2022-09-12 Impact factor: 3.752